Details For Selected Brain Tumor Treatment

Sponsored By

Please Click On The Above Banner For More Details

Last updated refers to the date when our listing for each treatment was last updated.
ID is our internal ID - starting with VT.
Min Karnofsky is a general guide to how well you have to function to use this treatment
For trials that also have a NCT number, you can click that number to pop up the listing from the clinicaltrials.gov website.

Back to New Treatments List



		Treatment Name:		Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms

		Keywords:		I-3F8

		Phase:		Phase 2

		Treatment ID#s:		VT1808 NCT00445965

		Age Group:		Adult And Pediatric

		Min Karnofsky Score:		Not Specified

		Conditions:		Newly Diagnosed: Y Recurrent: Y Prior Surgery is Sometimes Allowed Prior Radiation is Not Allowed Prior Chemotherapy is Allowed

		Last Updated:		08/20/2007

		Tumor Types:		Anaplastic Astrocytoma Glioblastoma Multiforme Gliosarcoma Medulloblastoma Metastatic Brain Tumor PNET Tumor


		Comments:		Medulloblastoma or primitive neuroectodermal tumor of the CNS High-grade astrocytoma Malignant glioma Neuroblastoma Retinoblastoma Ependymoma Rhabdoid tumors Sarcomas Melanoma Small cell lung carcinoma Desmoplastic small round cell tumor Other tumor types with GD2 expression confirmed by immunohistochemical staining and assessed by the Memorial Sloan-Kettering Department of Pathology using prior frozen tissue, bone marrow, or cerebrospinal fluid cytology

		Treatment Type:		Immunological, Biological or Targeted Therapy.

		Contact:		Memorial Sloan-Kettering Cancer Center Kim Kramer, MD New York, NY 10021 Phone: 212-639-6410 Click here to send an email

Translate this pageMicrosoftÂ® Translator

Copyright (c) 1993 - 2010 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740

Website Design By